ARNA Arena Pharmaceuticals Inc.

43.92
-0.14  -0%
Previous Close 44.06
Open 43.98
Price To Book 3.58
Market Cap 2172408328
Shares 49,462,849
Volume 197,229
Short Ratio
Av. Daily Volume 445,017

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated March 2017.
Etrasimod
Pyoderma gangrenosum (PG)
Phase 2 trial initiated March 2017.
Etrasimod
Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)
Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2/3 trial to be initiated 2019.
Olorinab (APD371)
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 3 trial to be initiated 2019.
Etrasimod
Ulcerative colitis
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 2 trial to be initiated 2019.
Etrasimod
Atopic dermatitis (AD)

Latest News

  1. Top Marijuana Stocks on the NASDAQ
  2. What Type Of Shareholder Owns Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA)?
  3. Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10
  4. Analysts Love Charlotte’s Web Holdings despite Q4 Earnings Miss
  5. Charlotte’s Web Holdings Reports Record Harvest in 2018
  6. Why Is Arena Pharmaceuticals (ARNA) Down 10.1% Since Last Earnings Report?
  7. Charlotte’s Web Holdings Is Outperforming Peers in March
  8. New Research Coverage Highlights The Blackstone Group, Arena Pharmaceuticals, Arrow Electronics, AdvanSix, KBR, and RPM International — Consolidated Revenues, Company Growth, and Expectations for 2019
  9. These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts
  10. Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation
  11. Edited Transcript of ARNA earnings conference call or presentation 26-Feb-19 9:30pm GMT
  12. United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
  13. Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues
  14. Arena Pharmaceuticals Inc (ARNA) Q4 2018 Earnings Conference Call Transcript
  15. Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
  16. 5 Clinical-Stage Biotech Stocks to Buy
  17. Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
  18. Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26
  19. Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress